15 results on '"Myles, Nicholas"'
Search Results
2. A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia.
- Author
-
Myles, Nicholas, Myles, Hannah, Xia, Shelley, Large, Matthew, Bird, Robert, Galletly, Cherrie, Kisely, Steve, and Siskind, Dan
- Subjects
- *
NEUTROPENIA , *ANTIPSYCHOTIC agents , *CLOZAPINE , *CONFIDENCE intervals , *MEDICAL information storage & retrieval systems , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *META-analysis , *NEUTROPHILS , *SYSTEMATIC reviews , *DATA analysis , *EFFECT sizes (Statistics) , *SEVERITY of illness index , *DISEASE risk factors - Abstract
Background: In most countries, clozapine can only be prescribed with regular monitoring of white blood cell counts because of concerns that clozapine has a stronger association with neutropenia than other antipsychotics. However, this has not been previously demonstrated conclusively with meta-analysis of controlled studies. Methods: The aim of this study was to assess the strength of the association between clozapine and neutropenia when compared to other antipsychotic medications by a meta-analysis of controlled studies. An electronic search of Medline (1948–2018), PsycINFO (1967–2018) and Embase (1947–2018) using search terms (clozapine OR clopine OR clozaril OR zaponex) AND (neutropenia OR agranulocytosis) was undertaken. Random-effects meta-analysis using Mantel–Haenszel risk ratio was used to assess the strength of the effect size. Results: We located 20 studies that reported rates of neutropenia associated with clozapine and other antipsychotic medications. The risk ratio was not significantly increased in clozapine-exposed groups compared to exposure to other antipsychotic medications (Mantel–Haenszel risk ratio = 1.45, 95% confidence interval = [0.87, 2.42]). This also applied to severe neutropenia (absolute neutrophil count < 500 per µL) when compared to other antipsychotics (Mantel–Haenszel risk ratio = 1.65, 95% confidence interval = [0.58, 4.71]). The relative risk of neutropenia associated with clozapine exposure was not significantly associated with any individual antipsychotic medication. Conclusion: Data from controlled trials do not support the belief that clozapine has a stronger association with neutropenia than other antipsychotic medications. This implies that either all antipsychotic drugs should be subjected to haematological monitoring or monitoring isolated to clozapine is not justified. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.
- Author
-
Myles, Nicholas, Myles, Hannah, Clark, Scott R., Bird, Robert, and Siskind, Dan
- Subjects
- *
GRANULOCYTE-colony stimulating factor , *CLOZAPINE , *NEUTROPENIA , *SYSTEMATIC reviews , *DESCRIPTIVE statistics , *PREVENTION , *THERAPEUTICS ,DRUG therapy for schizophrenia - Abstract
Background: Clozapine is the most effective medication for treatment-refractory schizophrenia; however, its use is contraindicated in people who have had previous clozapine-induced neutropenia. Co-prescription of granulocyte-colony stimulating factor may prevent recurrent neutropenia and allow continuation or rechallenge of clozapine. Objective and methods: Systematic review of literature reporting the use of granulocyte-colony stimulating factor to allow rechallenge or continuation of clozapine in people with previous episodes of clozapine-induced neutropenia. The efficacy of granulocyte-colony stimulating factor and predictors of successful rechallenge will be determined to elucidate whether evidence-based recommendations can be made regarding the use of granulocyte-colony stimulating factor in this context. Results: A total of 17 articles were identified that reported on clozapine rechallenge with granulocyte-colony stimulating factor support. In all, 76% of cases were able to continue clozapine at median follow-up of 12 months. There were no clear clinical or laboratory predictors of successful rechallenge; however, initial neutropenia was more severe in successful cases compared to unsuccessful cases. Cases co-prescribed lithium had lower success rates of rechallenge (60%) compared to those who were not prescribed lithium (81%). The most commonly reported rechallenge strategy was use of filgrastim 150-480 µg between daily to three times a week. There were no medication-specific side effects of granulocyte-colony stimulating factor reported apart from euphoria in one case. Three cases who failed granulocyte-colony stimulating factor had bacterial infection at time of recurrent neutropenia. No deaths were reported. Conclusion: Preliminary data suggest granulocyte-colony stimulating factor is safe and effective in facilitating rechallenge with clozapine. Clinical recommendations for use are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Australia’s economic transition, unemployment, suicide and mental health needs.
- Author
-
Myles, Nicholas, Large, Matthew, Myles, Hannah, Adams, Robert, Liu, Dennis, and Galletly, Cherrie
- Subjects
- *
SUICIDE risk factors , *UNEMPLOYMENT & psychology , *LABOR market , *LABOR supply , *MEDICAL needs assessment , *MENTAL health services , *PSYCHOLOGICAL stress , *MANUFACTURING industries - Abstract
Objective: There have been substantial changes in workforce and employment patterns in Australia over the past 50 years as a result of economic globalisation. This has resulted in substantial reduction in employment in the manufacturing industry often with large-scale job losses in concentrated sectors and communities. Large-scale job loss events receive significant community attention. To what extent these mass unemployment events contribute to increased psychological distress, mental illness and suicide in affected individuals warrants further consideration. Methods: Here we undertake a narrative review of published job loss literature. We discuss the impact that large-scale job loss events in the manufacturing sector may have on population mental health, with particular reference to contemporary trends in the Australian economy. We also provide a commentary on the expected outcomes of future job loss events in this context and the implications for Australian public mental health care services. Results and conclusion: Job loss due to plant closure results in a doubling of psychological distress that peaks 9 months following the unemployment event. The link between job loss and increased rates of mental illness and suicide is less clear. The threat of impending job loss and the social context in which job loss occurs has a significant bearing on psychological outcomes. The implications for Australian public mental health services are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use.
- Author
-
Myles, Hannah, Myles, Nicholas, and Large, Matthew
- Subjects
- *
AGE distribution , *CANNABIS (Genus) , *CINAHL database , *CONFIDENCE intervals , *MEDICAL information storage & retrieval systems , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *CLASSIFICATION of mental disorders , *META-analysis , *NOSOLOGY , *POPULATION geography , *PSYCHOSES , *REGRESSION analysis , *TIME , *EFFECT sizes (Statistics) , *DESCRIPTIVE statistics , *ODDS ratio - Abstract
Objectives: Cannabis use is prevalent among people with first episode psychosis and the epidemiology of its use in early psychosis is unclear. We performed a meta-analysis of observational studies to determine; (1) the interval between age at initiation of cannabis use and age at onset of first episode psychosis, (2) the prevalence of cannabis use at time of first episode psychosis, and (3) the odds of continuing cannabis following treatment for first episode psychosis. Data sources: Search of electronic databases MEDLINE, EMBASE, PsycINFO, Web of Science and CINAHL for English-language papers using search terms (psychosis OR schizophrenia) AND (cannabis OR marijuana) IN (title OR keyword OR abstract), current to October 2014. Study selection: Studies were included if they reported on prevalence of current cannabis use in first episode psychosis cohorts. A total of 37 samples were included for meta-analysis. Data extraction: Rates of cannabis use in each sample were extracted to determine prevalence estimates. The age at initiation of regular cannabis and age at onset of psychosis were used to determine the length of cannabis use preceding psychosis. Prevalence estimates at first episode psychosis and various time points of follow-up following first episode psychosis were analysed to determine odds ratio of continuing cannabis use. Data synthesis was performed using random-effects meta-analyses. Results: The pooled estimate for the interval between initiation of regular cannabis use and age at onset of psychosis was 6.3 years (10 samples, standardised mean difference = 1.56, 95% confidence interval = [1.40, 1.72]). The estimated prevalence of cannabis use at first episode psychosis was 33.7% (35 samples, 95% confidence interval = [31%, 39%]). Odds of continued cannabis use between 6 months and 10 years following first episode psychosis was 0.56 (19 samples, 95% confidence interval = [0.40, 0.79]). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Obstructive sleep apnea and schizophrenia: A systematic review to inform clinical practice.
- Author
-
Myles, Hannah, Myles, Nicholas, Antic, Nick A., Adams, Robert, Chandratilleke, Madhu, Liu, Dennis, Mercer, Jeremy, Vakulin, Andrew, Vincent, Andrew, Wittert, Gary, and Galletly, Cherrie
- Subjects
- *
HYPNAGOGIA , *META-analysis , *SLEEP apnea syndromes , *SCHIZOPHRENIA , *PSYCHOSES , *SCHIZOPHRENIA treatment , *SLEEP apnea syndrome treatment , *SYSTEMATIC reviews , *DISEASE complications - Abstract
Background: Risk factors for obstructive sleep apnea (OSA) are common in people with schizophrenia. Identification and treatment of OSA may improve physical health in this population; however there are no guidelines to inform screening and management.Objectives: Systematic review to determine, in people with schizophrenia and related disorders: the prevalence of OSA; the prevalence of OSA compared to general population controls; the physical and psychiatric correlates of OSA, associations between antipsychotic medications and OSA; the impact of treatment of OSA on psychiatric and physical health; and the diagnostic validity of OSA screening tools.Data Sources: Medline, EMBASE, ISI Web of Science and PsycINFO electronic databases. Cohort, case-control and cross-sectional studies and RCTs reporting on prevalence of OSA in subjects with schizophrenia and related disorders were reviewed.Results: The prevalence of OSA varied between 1.6% and 52%. The prevalence of OSA was similar between people with schizophrenia and population controls in two studies. Diagnosis of OSA was associated with larger neck circumference, BMI>25, male sex and age>50years. There were no data on physical or psychiatric outcomes following treatment of OSA. The diagnostic utility of OSA screening tools had not been investigated.Conclusion: OSA may be prevalent and potentially under-recognized in people with schizophrenia. Further research is required to determine utility of OSA screening tools, the relationships between antipsychotic medications and OSA and any benefits of treating OSA. We propose a strategy for the identification of OSA in people with schizophrenia and related disorders. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations.
- Author
-
Myles, Nicholas, Newall, Hannah, Ward, Harvey, and Large, Matthew
- Subjects
- *
CINAHL database , *CONFIDENCE intervals , *EPIDEMIOLOGY , *MEDICAL information storage & retrieval systems , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *META-analysis , *SEROTONIN uptake inhibitors , *SYSTEMATIC reviews , *DATA analysis , *DRUG-induced abnormalities - Abstract
The article offers information on a study conducted by the authors related to the association between antidepressants selective serotonin reuptake inhibitors (SSRIs) and malformations in heart of infants, whose mothers take these antidepressants. It states that paroxetine and fluoxetine caused malformations in infants. It highlights that citalopram and sertraline did not cause much problem in infants.
- Published
- 2013
- Full Text
- View/download PDF
8. The age at onset of psychosis and tobacco use: a systematic meta-analysis.
- Author
-
Myles, Nicholas, Newall, Hannah, Compton, Michael, Curtis, Jackie, Nielssen, Olav, and Large, Matthew
- Subjects
- *
PSYCHOSES , *TOBACCO use , *META-analysis , *SCHIZOPHRENIA , *CANNABIS (Genus) , *PATHOLOGICAL psychology , *MENTAL illness , *PSYCHOLOGY - Abstract
Background: There is a well-established but poorly understood association between tobacco use and psychotic illness. The aim of this study was to determine whether tobacco use is associated with an earlier age at onset of psychotic illness. Methods: Peer-reviewed publications in English reporting the age at onset of psychosis in tobacco-using and non-tobacco-using groups were located using searches of CINAHL, EMBASE, MEDLINE, PsycINFO and ISI Web of Science, and were supplemented by papers located by manual searches and unpublished data obtained by correspondence with primary researchers. A total of 29 samples reported age at onset data in a consecutive series of patients with a diagnosis of schizophrenia related psychosis or first episode psychosis. Information on study design, study population and effect size was extracted independently by three authors. A random effects meta-analysis was performed. Results: There was no significant difference between smokers and non-smokers in age at the onset of psychosis (standardized mean difference = −0.03). Conclusion: Unlike cannabis use, tobacco use is not associated with an earlier onset of psychosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Obstructive sleep apnoea is more prevalent in men with schizophrenia compared to general population controls: results of a matched cohort study.
- Author
-
Myles, Hannah, Vincent, Andrew, Myles, Nicholas, Adams, Robert, Chandratilleke, Madhu, Liu, Dennis, Mercer, Jeremy, Vakulin, Andrew, Wittert, Gary, and Galletly, Cherrie
- Subjects
- *
SLEEP apnea syndromes , *SCHIZOPHRENIA , *BODY mass index , *PEOPLE with schizophrenia , *MENTAL health , *LONGITUDINAL method , *OBESITY , *PSYCHOSES , *QUESTIONNAIRES , *COMORBIDITY , *DISEASE prevalence - Abstract
Objectives:: Obstructive sleep apnoea (OSA) may be more common in people with schizophrenia compared to the general population, but the relative prevalence is unknown. Here, we determine the relative prevalence of severe OSA in a cohort of men with schizophrenia compared to representative general population controls, and investigate the contribution of age and body mass index (BMI) to differences in prevalence.Methods:: Rates of severe OSA (apnoea-hypopnoea index > 30) were compared between male patients with schizophrenia and controls from a representative general population study of OSA.Results:: The prevalence of severe OSA was 25% in the schizophrenia group and 12.3% in the general population group. In subgroups matched by age, the relative risk of severe OSA was 2.9 ( p = 0.05) in the schizophrenia subjects, but when adjusted for age and BMI, the relative risk dropped to 1.7 and became non-significant ( p = 0.17).Conclusions:: OSA is prevalent in men with schizophrenia. Obesity may be an important contributing factor to the increased rate of OSA. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Meta-Analysis of Longitudinal Cohort Studies of Suicide Risk Assessment among Psychiatric Patients: Heterogeneity in Results and Lack of Improvement over Time.
- Author
-
Large, Matthew, Kaneson, Muthusamy, Myles, Nicholas, Myles, Hannah, Gunaratne, Pramudie, and Ryan, Christopher
- Subjects
- *
PSYCHOTHERAPY patients , *SUICIDE risk factors , *MEDICAL care , *CATEGORIZATION (Psychology) , *COHORT analysis , *META-analysis - Abstract
Objective: It is widely assumed that the clinical care of psychiatric patients can be guided by estimates of suicide risk and by using patient characteristics to define a group of high-risk patients. However, the statistical strength and reliability of suicide risk categorization is unknown. Our objective was to investigate the odds of suicide in high-risk compared to lower-risk categories and the suicide rates in high-risk and lower-risk groups. Method: We located longitudinal cohort studies where psychiatric patients or people who had made suicide attempts were stratified into high-risk and lower-risk groups for suicide with suicide mortality as the outcome by searching for peer reviewed publications indexed in PubMed or PsychINFO. Electronic searches were supplemented by hand searching of included studies and relevant review articles. Two authors independently extracted data regarding effect size, study population and study design from 53 samples of risk-assessed patients reported in 37 studies. Results: The pooled odds of suicide among high-risk patients compared to lower-risk patients calculated by random effects meta-analysis was of 4.84 (95% Confidence Interval (CI) 3.79–6.20). Between-study heterogeneity was very high (I2 = 93.3). There was no evidence that more recent studies had greater statistical strength than older studies. Over an average follow up period of 63 months the proportion of suicides among the high-risk patients was 5.5% and was 0.9% among lower-risk patients. The meta-analytically derived sensitivity and specificity of a high-risk categorization were 56% and 79% respectively. There was evidence of publication bias in favour of studies that inflated the pooled odds of suicide in high-risk patients. Conclusions: The strength of suicide risk categorizations based on the presence of multiple risk factors does not greatly exceed the association between individual suicide risk factors and suicide. A statistically strong and reliable method to usefully distinguish patients with a high-risk of suicide remains elusive. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Neutrophil-lymphocyte ratio - a simple, accessible measure of inflammation, morbidity and prognosis in psychiatric disorders?
- Author
-
Zulfic, Zlatan, Weickert, Cynthia Shannon, Weickert, Thomas W, Liu, Dennis, Myles, Nicholas, and Galletly, Cherrie
- Subjects
- *
MENTAL illness , *BLOOD testing , *DISEASES , *PROGNOSIS , *INFLAMMATION , *LYMPHOCYTES , *NEUTROPHILS , *LEUKOCYTE count ,PSYCHIATRIC research - Abstract
Objective: A narrative review to describe the utility of the neutrophil-lymphocyte ratio (NLR) as an inflammatory marker in psychiatric and non-psychiatric disorders and to discuss the potential role of NLR in psychiatric research.Conclusions: NLR is inexpensive and readily available using division of two measures obtained on routine blood testing. NLR is elevated in a number of psychiatric disorders. It can predict morbidity and mortality in a wide range of non-psychiatric conditions, but this has not been confirmed in psychiatric conditions. It can be calculated in large, pre-existing datasets to investigate clinical correlates of inflammatory processes. NLR may have a future role in identifying patients with an inflammatory phenotype who could benefit from adjunctive anti-inflammatory medications. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy.
- Author
-
Siskind, Dan, Sidhu, Ashneet, Cross, John, Chua, Yee-Tat, Myles, Nicholas, Cohen, Dan, and Kisely, Steve
- Subjects
- *
CLOZAPINE , *CONFIDENCE intervals , *DIABETES , *DRUG side effects , *MEDICAL information storage & retrieval systems , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *META-analysis , *CARDIOMYOPATHIES , *ONLINE information services , *RISK assessment , *SYSTEMATIC reviews , *COMORBIDITY , *METABOLIC syndrome , *DISEASE incidence , *DISEASE risk factors ,DRUG therapy for schizophrenia ,MORTALITY risk factors - Abstract
Background: Clozapine is the most effective medication for treatment refractory schizophrenia, but is associated with cardiac adverse drug reactions. Myocarditis and cardiomyopathy are the most serious cardiac adverse drug reactions although reported rates of these conditions vary in the literature. We systematically reviewed and meta-analysed the event rates, the absolute death rates and case fatality rates of myocarditis and cardiomyopathy associated with clozapine. Methods: PubMed, EMBASE and PsycINFO were searched for studies that reported on the incidence of cardiomyopathy or myocarditis in people exposed to clozapine. Data were meta-analysed using a random effects model, with subgroup analysis on study size, time frame, region, quality, retrospective vs prospective, and diagnostic criteria of myocarditis or cardiomyopathy. Results: 28 studies of 258,961 people exposed to clozapine were included. The event rate of myocarditis was 0.007 (95% confidence interval [CI] = [0.003, 0.016]), absolute death rate was 0.0004 (95% CI = [0.0002, 0.0009]) and case fatality rate was 0.127 (95% CI = [0.034, 0.377]). The cardiomyopathy event rate was 0.006 (95% CI = [0.002, 0.023]), absolute death rate was 0.0003 (95% CI = [0.0001, 0.0012]) and case fatality rate was 0.078 (95% CI = [0.018, 0.285]). Few included studies provided information on criteria for diagnosis of myocarditis and cardiomyopathy. Event rates of cardiomyopathy and myocarditis were higher in Australia. Conclusion: Clarity of diagnostic criteria for myocarditis remains a challenge. Observation bias may, in part, influence higher reported rates in Australia. Monitoring for myocarditis is warranted in the first 4 weeks, and treatment of comorbid metabolic syndrome and diabetes may reduce the risk of cardiomyopathy. The risks of myocarditis and cardiomyopathy are low and should not present a barrier to people with treatment refractory schizophrenia being offered a monitored trial of clozapine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. A cohort study assessing the impact of small volume blood tubes on diagnostic test quality and iatrogenic blood loss in a cohort of adult haematology patients.
- Author
-
von Wielligh, Jacoba, Kyriacou, Mario, To, Luen B., Myles, Nicholas, and Ventrice, Terry
- Subjects
- *
IATROGENIC diseases , *BLOOD testing , *BLOOD vessels , *ETHYLENEDIAMINETETRAACETIC acid , *FIBRIN , *HOSPITAL care , *LONGITUDINAL method , *BLOOD loss estimation , *TERTIARY care , *DIAGNOSIS ,RESEARCH evaluation - Abstract
Abstract: Background/Aim: To estimate the reduction in blood volume loss and impact on diagnostic test quality associated with introduction of small volume blood tubes in a cohort of haematology inpatients compared to a historical comparator group. Methods: Prospective cohort study of haematology inpatients admitted to a tertiary referral hospital in Adelaide. Small volume blood tubes were used in an intervention cohort admitted between 2012 and 2013 and compared to a control cohort admitted between 2009 and 2010 where standard volume blood tubes had been used. The diagnostic test quality, specimen integrity and total reduction in blood loss associated with small volume blood tubes were estimated. Results: Small volume blood tubes demonstrated acceptable collinearity on commonly assayed haematological and biochemical parameters. Small volume tubes were associated with a 42% reduction in blood volume loss equating to a saving of 8.5 mL per patient per day or 180 mL of blood loss over a 3‐week admission. Small volume blood tubes were associated with a slight but significantly increased rate of fibrin contamination of ethylenediaminetetraacetic acid samples (0.2–0.5% of specimens). Conclusion: Small volume blood tubes are associated with a substantial reduction in total blood volume collected per day in haematology inpatients. They have similar diagnostic validity and sample integrity to that of standard volume containers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.
- Author
-
Hollingworth, Samantha A., Winckel, Karl, Saiepour, Nargess, Wheeler, Amanda J., Myles, Nicholas, and Siskind, Dan
- Subjects
- *
CLOZAPINE , *ANTIDEPRESSANTS , *BICYCLIC diazepines , *ADVERSE health care events , *NEUTROPENIA - Abstract
Rationale: Clozapine is the gold-standard medicine for treating refractory schizophrenia but there are some notable serious adverse events (AE). We aimed to analyse reported rates of clozapine cardiac and haematological AEs in Australia.Methods: Using data from the Therapeutic Goods Administration, we examined all reported clozapine AEs (1993-2014) with a specific focus on neutropenia, myocarditis and cardiomyopathy. We related AEs to clozapine-dispensing data in Queensland, scaled up to Australia.Results: There were 8561 AEs reported: neutropenia (13.7%), myocarditis (9.3%) and cardiomyopathy (3.8%). Reported rates of myocarditis and cardiomyopathy increased after 1999 following a myocarditis case series from Sydney. Cardiomyopathy AE rates have remained stable since then but myocarditis AEs have increased steadily. Neutropenia was more common in women, while cardiomyopathy and myocarditis were more common in men. There were five reported deaths from neutropenia and cardiomyopathy.Conclusions: The rates of serious AEs (including deaths) are low and likely an underestimate of true rates and need to be considered by clinicians in balancing the risks and benefits. Continued education on the monitoring and treatment of these AEs for consumers, carers and health professionals is essential and reporting these to the relevant national reporting agency is crucial. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Correction to: Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.
- Author
-
Hollingworth, Samantha A., Winckel, Karl, Saiepour, Nargess, Wheeler, Amanda J., Myles, Nicholas, and Siskind, Dan
- Subjects
- *
CLOZAPINE , *NEUTROPENIA , *ANTIDEPRESSANTS - Abstract
The authors would like to change the statement found in the results section of the abstract from "There were five reported deaths from neutropenia and cardiomyopathy." to "There were five, 13, and two reported deaths from neutropenia, myocarditis, and cardiomyopathy, respectively." [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.